Lancet Confirms New Managing Director

Pathologists Lancet Kenya has confirmed the appointment of Mwende Musunga as Managing Director and Chief Executive Officer of PLK East Africa.

Musunga was already working as CEO. She was one of three appointees who replaced the towering Ahmed Kelebi in March 2021.

Kalebi’s official title was Group Managing Director, CEO and Chief Consultant Pathologist – highlighting the different roles he took on at the organization before his exit. The roles were split between Mwende Musunga as Group CEO, Matthieu Goge as Group Managing Director and Dr. Charles Wahome as Chief Consultant Pathologist.

Going forward, Musunga will serve as CEO and Managing Director. She will lead a team of over 400 employees across the region.

“We are delighted to confirm the appointment of Musunga as the managing director who will continue to lead the company. Under her leadership, we will be able to widen our network, catering to more patients and partnering with more hospitals, increasing access to quality and affordable tests, and consequently improving the healthcare of the communities we serve,” said Chair to the Board of Directors, Stéphane Carré.

READ>>Irreplaceable CEO? Lancet Appoints 3 People to Take Over from Kalebi

Musunga welcomed her appointment, promising to uphold high standards as she steers the company forward.

“My goal is to ensure that we maintain and grow our positive brand offering as we drive innovation & changes within our organization, to reach more people across East Africa. I am honoured to work with leading pathologists, with whom, we will contribute to the strengthening of our healthcare systems,” she asserted.

In October 2009, Kalebi was instrumental in founding Lancet Kenya, an off-shoot of its South African parent company – Lancet Laboratories South Africa. It operated under Pathologist Lancet Kenya (PLK) and Lancet Services Company (LSC), of which Kelebi reportedly owns 7.67 per cent and 10 per cent respectively. French multinational Cerba Healthcare bought shares in Lancet Laboratories (SA) in a 2019 deal that also saw it take a controlling stake of its Kalebi-led East Africa business.

The breadth of his work at the company was perhaps best illustrated in the Ksh1.9 billion pay-out he sought ahead of his exit. Among other employment claims, Kalebi wanted accrued overtime amounting to Ksh473,523,080 since 2009.

READ>>Lancet CEO Kalebi Wants Ksh2 Billion to Walk Away from Firm He Built